Full Alliance Group (OTC:FAGI) Stock, Quote.Headers.trade-ideas

Full Alliance Group Inc provides nutraceutical and supplement products; extracorporeal blood oxygenation and ozonation treatments for patients. The company derives revenues from merchandise sales from physical locations and online channels.

FULL ALLIANCE GROUP INC by Full Alliance Group, Inc.

Full Alliance Group Inc

<p>Maxim Group  analyst Tate Sullivan   maintains 5E Advanced Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEAM#NASDAQ">FEAM</a>) with a Buy and lowers the price target from $4 to $1.25.</p>


News

Price Target

Analyst Ratings

FEAM

Maxim Group Maintains Buy on 5E Advanced Materials, Lowers Price Target to $1.25

Legal

Office Of The Comptroller Of The Currency Issues Enforcement Action Vs Wells Fargo Bank

WIIM

MELI

MercadoLibre shares are trading higher after B of A Securities maintained a Buy rating and raised its price target to $2,500.

<p><a href="https://www.bleepingcomputer.com/news/security/fortinet-confirms-data-breach-after-hacker-claims-to-steal-440gb-of-files/" title="https://www.bleepingcomputer.com/news/security/fortinet-confirms-data-breach-after-hacker-claims-to-steal-440gb-of-files/">https://www.bleepingcomputer.com/news/security/fortinet-confirms-data-breach-after-hacker-claims-to-steal-440gb-of-files/</a></p>


FTNT

'Fortinet confirms data breach after hacker claims to steal 440GB of files' - BleepingComputer

<p>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 21.08%. Currently, UnitedHealth Group has a market capitalization of $543.84 billion. </p>
<p><strong>Buying $100 In UNH:</strong> If an investor had bought $100 of UNH stock 10 years ago, it would be worth <strong>$675.69</strong> today based on a price of $588.94 for UNH at the time of writing.</p>
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726164177_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

If You Invested $100 In This Stock 10 Years Ago, You Would Have $700 Today

<p>Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) has outperformed the market over the past 5 years by 10.58% on an annualized basis producing an average annual return of 23.75%. Currently, Marvell Tech has a market capitalization of $65.00 billion. </p>
<p><strong>Buying $100 In MRVL:</strong> If an investor had bought $100 of MRVL stock 5 years ago, it would be worth <strong>$295.47</strong> today based on a price of $75.04 for MRVL at the time of writing.</p>
<h3>Marvell Tech's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726164173_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MRVL

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

<p>Evercore ISI Group  analyst James West   maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Outperform and raises the price target from $202 to $240.</p>


Evercore ISI Group Maintains Outperform on GE Vernova, Raises Price Target to $240

PTON

Peloton Announcing Series Of Adjustments To Retail Price

<p>U.S. stocks traded higher toward the end of trading, with the Dow Jones index surging more than 200 points on Thursday.</p>
<p>The Dow traded up 0.53% to 41,076.41 while the NASDAQ rose 1.15% to 17,596.13. The S&amp;P 500 also rose, gaining, 0.82% to 5,599.94.</p>
<p>Check This Out: <a href="https://www.benzinga.com/news/24/09/40812617/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-delivering-high-dividend-y">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields</a></p>
<p><strong>Leading and Lagging Sectors</strong><br /><br />Communication services shares rose by 1.2% on Thursday.</p>
<p>In trading on Thursday, real estate shares dipped by 0.8%.</p>
<p><strong>Top Headline</strong></p>
<p><strong>Signet Jewelers Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) posted better-than-expected second-quarter earnings and stronger than anticipated third-quarter revenue outlook.</p>
<p>Signet reported a second-quarter sales decline of 7.6% year-on-year to $1.49 billion, missing the analyst consensus estimate of $1.50 billion. Adjusted EPS of $1.25 beat the analyst consensus estimate of $1.14.</p>
<p><strong>Equities Trading UP</strong><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<ul>
<li><strong>NETGEAR, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) shares shot up 31% to $20.83 after the company disclosed a settlement agreement with TP-Link Systems and raised its third-quarter revenue guidance.</li>
<li>Shares of <strong>Visionary Holdings Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) got a boost, surging 144% to $4.95 after the company announced it signed an MoU with the Public Investment Fund of Saudi Arabia, investing $120 million to fully support the development of its various industry projects.</li>
<li><strong>Smart for Life, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) shares were also up, gaining 32% to $1.12. HRT Financial LP acquired a new stake in Smart for Life.</li>
</ul>
<p><strong>Equities Trading DOWN</strong></p>
<ul>
<li><strong>ModivCare Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares dropped 53% to $14.56 after the company announced a $200 million mixed securities shelf.</li>
<li>Shares of <strong>Fulcrum Therapeutics, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) were down 61% to $3.4850 after the company announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.</li>
<li><strong>Oncternal Therapeutics, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) was down, falling 57% to $1.7250 after the company announced termination of its clinical studies and exploration of strategic alternatives.</li>
</ul>
<p><strong>Commodities</strong><br /><br />In commodity news, oil traded up 3.3% to $69.53 while gold traded up 1.3% at $2,576.20.</p>
<p>Silver traded up 3.9% to $30.05 on Thursday, while copper rose 1.1% to $4.1880.</p>
<p><strong>Euro zone</strong></p>
<p>European shares closed higher today. The eurozone's STOXX 600 rose 0.80%, Germany's DAX gained 1.03% and France's CAC 40 rose 0.52%. Spain's IBEX 35 Index rose 1.08%, while London's FTSE 100 rose 0.57%.</p>
<p>The annual inflation rate in Spain eased to 2.3% in August from 2.8% in July, while German wholesale prices fell by 1.1% year-over-year in August.</p>
<p><strong>Asia Pacific Markets</strong></p>
<p>Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 jumping 3.41%, Hong Kong's Hang Seng Index gaining 0.77%, China's Shanghai Composite Index falling 0.17% and India's BSE Sensex surging 1.77%.</p>
<p>Manufacturing production in Hong Kong increased 0.7% year-over-year during the second quarter. Producer prices in Japan rose by 2.5% year-over-year in August versus a 3.0% growth in the previous month.</p>
<p><strong>Economics</strong></p>
<ul>
<li>U.S. producer prices rose 0.2% month-over-month in August compared to a revised flat reading in the previous month and higher than market estimates of 0.1%.</li>
<li>U.S. initial jobless claims increased by 2,000 from the earlier week to 230,000 in the week ending Sept. 7.</li>
<li>U.S. natural-gas stocks rose 40 billion cubic feet during the week ended Sept. 6, compared to market estimates of a 49 bcf gain.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40828657/top-3-tech-stocks-youll-regret-missing-in-september">Top 3 Tech Stocks You&#8217;ll Regret Missing In September</a></strong></li>
</ul>


Equities

Eurozone

Commodities

Intraday Update

Markets

FULC

MODV

NTGR

ONCT

SMFL

Dow Surges Over 100 Points; ModivCare Shares Plummet

<p>Across the recent three months, 10 analysts have shared their insights on Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Nu Holdings, revealing an average target of $15.42, a high estimate of $17.00, and a low estimate of $13.50. This upward trend is evident, with the current average reflecting a 12.06% increase from the previous average price target of $13.76.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726164074_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Nu Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$12.80</td>
</tr>
<tr>
<td>Domingos Falavina</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$14.50</td>
</tr>
<tr>
<td>John Coffey</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Thiago Batista</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$13.50</td>
<td>-</td>
</tr>
<tr>
<td>Domingos Falavina</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Mike Niehuser</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>John Coffey</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Inigo Vega</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.20</td>
<td>$10.80</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Nu Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nu Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Nu Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Nu Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NU/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Nu Holdings analyst ratings.</strong></a></p>
<h2>Delving into Nu Holdings's Background</h2>
<p>Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Accounts, and Rewards. The company earns the majority of its revenue in Brazil.</p>
<h3>Unraveling the Financial Story of Nu Holdings</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Nu Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>55.21%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Nu Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>23.37%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Nu Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.1%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Nu Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.1%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.26</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 10 Takes On Nu Holdings

EXAS

Exact Sciences shares are trading higher after Piper Sandler raised its price target on the stock from $75 to $85.

<p>Analysts' ratings for EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $41.3, with a high estimate of $55.00 and a low estimate of $32.00. Experiencing a 6.94% decline, the current average is now lower than the previous average price target of $44.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726164064_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of EQT's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$32.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Cameron Bean</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$55.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to EQT. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of EQT compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of EQT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into EQT's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EQT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on EQT analyst ratings.</strong></a></p>
<h2>Discovering EQT: A Closer Look</h2>
<p>EQT Corp is an independent natural gas production company with operations focused in the Marcellus and Utica shale plays in the Appalachian Basin. At year-end 2023, EQT's proven reserves totaled 27.6 trillion cubic feet equivalent, with net production of 5.79 billion cubic feet equivalent per day. Natural gas accounted for 94% of production.</p>
<h3>EQT's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining EQT's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.31%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> EQT's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>1.07%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> EQT's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.06%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> EQT's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.04%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.33</strong>, EQT adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 10 Analyst Recommendations For EQT

<p>Throughout the last three months, 12 analysts have evaluated Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Advance Auto Parts, revealing an average target of $56.17, a high estimate of $73.00, and a low estimate of $38.00. Highlighting a 12.23% decrease, the current average has fallen from the previous average price target of $64.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726164056_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Advance Auto Parts by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$56.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Scott Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$46.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$60.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Max Rakhlenko</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$70.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Advance Auto Parts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Advance Auto Parts compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Advance Auto Parts's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Advance Auto Parts's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AAP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Advance Auto Parts analyst ratings.</strong></a></p>
<h2>About Advance Auto Parts</h2>
<p>Advance Auto Parts is a leading auto parts retailer in North America with more than 5,000 store and branch locations. About 60% of the firm's sales are geared toward the professional channel, with the remaining 40% going to the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units conducive to various vehicle makes and models. The retailer primarily competes on the basis of inventory availability and service speed, making the operating efficiency of its hub and spoke distribution model critical to meeting customer needs.</p>
<h3>Advance Auto Parts's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Advance Auto Parts's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-0.11%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Advance Auto Parts's net margin is impressive, surpassing industry averages. With a net margin of <strong>1.68%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Advance Auto Parts's ROE excels beyond industry benchmarks, reaching <strong>1.73%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Advance Auto Parts's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.37%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Advance Auto Parts's debt-to-equity ratio is below the industry average. With a ratio of <b>1.52</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Advance Auto Parts Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

<p>HC Wainwright &amp; Co.  analyst Yi Chen   reiterates Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) with a Buy and maintains $2.5 price target.</p>


Reiteration

ICCM

HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $2.5 Price Target

<p>Throughout the last three months, 6 analysts have evaluated Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.67, a high estimate of $34.00, and a low estimate of $26.00. A decline of 7.54% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726164048_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Coterra Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$30.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Leo Mariani</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Coterra Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Coterra Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Coterra Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Coterra Energy's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTRA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Coterra Energy analyst ratings.</strong></a></p>
<h2>All You Need to Know About Coterra Energy</h2>
<p>Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and NGLs. The company's operations are primarily concentrated in three core operating areas; the Permian Basin in west Texas and southeast New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin in the Mid-Continent region in Oklahoma.</p>
<h3>Coterra Energy's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Coterra Energy displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>7.26%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Coterra Energy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>17.23%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Coterra Energy's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>1.68%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Coterra Energy's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>1.05%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Coterra Energy's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.23</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CTRA

What 6 Analyst Ratings Have To Say About Coterra Energy

<p>Deutsche Bank  analyst David Begleiter   maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Hold and lowers the price target from $57 to $53.</p>


Deutsche Bank Maintains Hold on Dow, Lowers Price Target to $53

<p>In the preceding three months, 9 analysts have released ratings for Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Exact Sciences, revealing an average target of $74.0, a high estimate of $85.00, and a low estimate of $67.00. Observing a downward trend, the current average is 12.8% lower than the prior average price target of $84.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726164020_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Exact Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exact Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Exact Sciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Exact Sciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Exact Sciences analyst ratings.</strong></a></p>
<h2>Delving into Exact Sciences's Background</h2>
<p>Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.</p>
<h3>Exact Sciences: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Exact Sciences showcased positive performance, achieving a revenue growth rate of <strong>12.41%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Exact Sciences's net margin is impressive, surpassing industry averages. With a net margin of <strong>-2.26%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Exact Sciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-0.5%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Exact Sciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.24%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.87</strong>, Exact Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For Exact Sciences

<p>21 analysts have shared their evaluations of BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $71.05, a high estimate of $100.00, and a low estimate of $45.00. Highlighting a 11.35% decrease, the current average has fallen from the previous average price target of $80.15. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726164009_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive BILL Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Poutrieux</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Outperform</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$57.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Peter Levine</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$91.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$45.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$59.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$86.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BILL Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BILL Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for BILL Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of BILL Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BILL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on BILL Holdings analyst ratings.</strong></a></p>
<h2>Get to Know BILL Holdings Better</h2>
<p>BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.</p>
<h3>BILL Holdings: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, BILL Holdings showcased positive performance, achieving a revenue growth rate of <strong>16.11%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> BILL Holdings's net margin is impressive, surpassing industry averages. With a net margin of <strong>2.21%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>0.19%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.08%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.24</strong>, BILL Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BILL

Expert Outlook: BILL Holdings Through The Eyes Of 21 Analysts

COIN

Coinbase shares are trading higher after the company announced the launch of Coinbase Wrapped BTC (cbBTC), a new ERC20 token backed 1:1 by Bitcoin held in Coinbase's custody to bridge Bitcoin to Ethereum and base networks.

<p><strong>Microsoft Corp</strong>'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) recent overhaul of Xbox Game Pass has brought significant changes to the subscription service, impacting how gamers access some of the industry's <a href="https://www.benzinga.com/general/gaming">anticipated titles. </a></p>
<p>As of Sept. 12, 2024, the newly introduced tiers are live, offering different levels of access — and leaving many to wonder whether the higher cost of Xbox Game Pass Ultimate is worth the expanded library, IGN <a href="https://www.ign.com/articles/xbox-game-pass-standard-tier-doesnt-include-call-of-duty-modern-warfare-3-starfield-diablo-4-and-more">reported.</a></p>
<p><strong>See Also: <a href="https://www.benzinga.com/general/gaming/24/07/39888849/microsoft-responds-to-ftcs-criticism-about-xbox-game-pass-asserting-it-is-wrong-to-call-this-a-deg">Microsoft Responds To FTC&#8217;s Criticism About Xbox Game Pass, Asserting &#8216;It Is Wrong To Call This A Degraded Version&#8217;</a></strong></p>
<h3 class="wp-block-heading">What Are the Differences Between Xbox Game Pass Tiers?</h3>
<p>Xbox Game Pass Ultimate, now priced at $19.99 per month (up from $16.99), remains the most comprehensive option for players. It includes day-one access to new titles, the full Xbox Game Pass library, PC Game Pass, EA Play, Xbox Cloud Gaming, online multiplayer, and a range of perks such as exclusive deals and discounts. </p>
<p>However, the newly launched Xbox Game Pass Standard costs $14.99 per month and offers far fewer benefits. Subscribers to this plan miss out on day-one releases, EA Play access, and the cloud gaming feature, limiting their experience to a smaller pool of Xbox titles.</p>
<p>Subscribers still using the now-defunct Game Pass for Console tier will continue to receive day-one games, but new users can no longer sign up for this option, making it a legacy tier reserved for existing customers at $10.99 per month.</p>
<p>Meanwhile, Xbox Game Pass Core at $9.99 per month offers online multiplayer alongside access to a rotating selection of about 25 games, in stark contrast to the 370 titles available under Game Pass Standard and the extensive library of 508 games reserved for Ultimate subscribers.</p>
<h3 class="wp-block-heading">Which<strong> Games Are Missing From Xbox Game Pass Standard</strong>?</h3>
<p>With the new tier system in place, subscribers opting for Xbox Game Pass Standard may feel the absence of some heavy-hitters. These notable exclusions include:</p>
<ul>
<li><em>Call of Duty: Modern Warfare 3</em></li>
<li><em>Starfield</em></li>
<li><em>Diablo 4</em></li>
<li><em>Forza Motorsport</em></li>
<li><em>MLB: The Show 24</em></li>
<li><em>Octopath Traveler 2</em></li>
<li><em>Payday 3</em></li>
<li><em>Age of Mythology: Retold</em></li>
</ul>
<p>The games listed above, among others, are now exclusive to Game Pass Ultimate for new subscribers, making the decision to upgrade a matter of balancing budget against access to premier titles.</p>
<h3 class="wp-block-heading"><strong>Game Library Breakdown</strong></h3>
<p>Game Pass Standard subscribers have access to 370 games, down from the 508 available under the Ultimate tier. </p>
<p>This includes the exclusion of the EA Play library—an extensive collection of games like FIFA 23 and Battlefield 2042, which are bundled exclusively with Xbox Game Pass Ultimate. To access these additional titles, users will need to make the jump to the $19.99 per month tier.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/08/40492071/xbox-game-pass-update-core-standard-tiers-face-up-to-12-month-wait-for-new-releases">Xbox Game Pass Update: Core, Standard Tiers Face Up To 12-Month Wait For New Releases</a></li>
</ul>
<p><em>Image credits: Shutterstock.</em></p>


MSFT

Microsoft's New Xbox Game Pass Tiers: Which Games Will You Lose?

Press Releases

Millionaires Club Founder and Top 100 Global MLM Earner Edgar Mojica Joins DYNAMAXX as Co-Founder: Full Alliance Group (OTC: "FAGI") Teams Up with Network Marketing Dynamo, Edgar Mojica, who will be Leading DYNAMAXX in its International Expansion, Product Reformulation and Relaunch

Dynamaxx Revitalizes its Product Portfolio, Launches Nine Enhanced and Newly Formulated Offerings: Full Alliance Group (OTC: "FAGI")

Full Alliance Group, Inc. Announces Craig Lane as President of its wholly owned subsidiary DYNAMAXX Health, Inc. (OTC: FAGI)

Full Alliance Group, Inc.'s (OTC:FAGI) Wholly Owned Subsidiary DynaMAXX Health, Inc. Launches PRiVIVE(TM) Topical Serum: A Revolutionary Solution for Cellular Rejuvenation and Dermal Health

Full Alliance Group, Inc. Congratulates Corinne Sanzone and Leslie DuRant of Our Clean Paws, Inc. on Their Feature on Fox & Friends

Full Alliance Group, Inc. (OTC: FAGI) and DynaMAXX Health, Inc. Announce its Grand Opening of the First Ever Cash Pay Anti-Aging and Rejuvenation Direct Sales MAXX Health Clinic, in The Villages, Florida

Full Alliance Group, Inc. (OTC: FAGI) Wholly Owned Subsidiary Dynamaxx Health Inc. Secures Its Own Manufacturing Contract for Medical Devices for MAXX Health Clinics

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Full Alliance Group

Full Alliance Group (FAGI) Forecast

Full Alliance Group (OTC:FAGI) Stock, Quote.Headers.trade-ideas